United States

Biotec Pharmacon ASA (BIOTEC.OL)

BIOTEC.OL on Oslo Stock Exchange

Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Biotec Pharmacon's CEO Svein W. F. Lien resigns due to health issues
Thursday, 16 Mar 2017 12:03pm EDT 

Biotec Pharmacon ASA : Biotec Pharmacon's CEO, Svein W. F. Lien resigns due to health issues . Says board has entered into agreement with Lien and will start recruitment process immediately .Says Lien is committed to continue in his full capacity as CEO until a successor is on board, at which time he will step down.  Full Article

Biotec Pharmacon Q4 EBITDA loss widens to NOK 8.1 mln
Thursday, 2 Feb 2017 01:00am EST 

Biotec Pharmacon ASA : Q4 revenue 18.2 million Norwegian crowns ($2.2 million)versus 13.1 million crowns year ago . Q4 EBITDA loss 8.1 million crowns versus loss nok 7.1 million year ago .Operational targets for 2017 are to finalize UK reimbursement, drive commercial sales for Woulgan, expand business opportunities within consumer and animal health segment.  Full Article

Biotec Pharmacon EBITDA loss widens to NOK 5.9 million
Wednesday, 26 Oct 2016 01:00am EDT 

Biotec Pharmacon ASA : Q3 revenue 21.1 million Norwegian crowns ($2.5 million) versus 16.4 million crowns year ago . Q3 EBITDA loss 5.9 million crowns versus loss 3.5 million crowns year ago .Reiterates its 2016 operational targets for Woulgan, presented at company's capital markets day on Feb. 11 2016.  Full Article

Biotec Pharmacon: Arcticzymes launches polymerase product, gets patent in US
Friday, 30 Sep 2016 02:00am EDT 

Biotec Pharmacon ASA : Says subsidiary ArcticZymes has launched its first DNA polymerase product onto market .ArcticZymes also received patent protection for its heat-labile Salt Active Nucleases (SAN) in USA.  Full Article

Biotec Pharmacon Q2 EBITDA loss widens to NOK 1.6 mln
Wednesday, 17 Aug 2016 01:00am EDT 

Biotec Pharmacon ASA : Q2 revenue 15.3 million Norwegian crowns ($1.86 million) versus 11.5 million crowns year ago . Q2 EBITDA loss 1.6 million crowns versus loss 1.0 million crowns year ago .Reiterates its 2016 operational targets for Woulgan.  Full Article

Biotec Pharmacon files 510K application for US market
Thursday, 30 Jun 2016 08:34am EDT 

Biotec Pharmacon ASA : Says will file 510K application for Woulgan for US market this week . Process normally takes 6-9 months .Expects feedback from authorities late in 2016 or early 2017.  Full Article

Biotec cleared in arbitration matter
Monday, 13 Jun 2016 07:03am EDT 

Biotec Pharmacon ASA : Received the decision by the arbitration court related to the Company's nutrition business brought up by company Sana Pharma AS .The decision by the arbitration court clears Biotec from all matters sought and the plaintiff will pay the litigation cost for both parties.  Full Article

Biotec Pharmacon signs German distribution agreement for Woulgan
Monday, 13 Jun 2016 07:02am EDT 

Biotec Pharmacon ASA : Enters into distribution agreement for Woulgan with the German distributor Rogg Verbandstoffe GmbH .Agreement is in line Biotec's outlook to secure one or more distribution agreement in Germany during 2016.  Full Article

Biotec Pharmacon ASA unit awarded funding from Horizon2020 programme
Friday, 1 Apr 2016 03:00am EDT 

Biotec Pharmacon ASA:ArcticZymes, a subsidiary of Biotec Pharmacon has received 460,000 euros over the next four years in a project funded by the European Framework Programme for Research and Innovation, Horizon 2020.  Full Article

Biotec Pharmacon ASA: Biotec BetaGlucans has entered into supply agreement for delivery of M-Glucan
Friday, 11 Mar 2016 01:30am EST 

Biotec Pharmacon ASA:Subsidiary Biotec BetaGlucans AS has entered into a supplier agreement with a new feed company for deliveries of its beta-glucan product M-Glucan for use in animal health.Deliveries under the agreement will commence from May 1, 2016 and run for 24 months.Expected revenues for the indicated period is around 20 million Norwegian crowns depending on sales ​.  Full Article

More From Around the Web